Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Pharma Opposes Off-Year Revision, but Payer Pushes Implementation as Premise
The Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ) on August 7 reiterated its call for abolishing “off-year” drug price revisions including one scheduled for FY2025, highlighting significant changes in the business environment. “The situation is not right,” FPMAJ Chairman…
To read the full story
Related Article
REGULATORY
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
September 17, 2026
- Ueno Retained as Health Minister in Takaichi Cabinet Reshuffle
September 17, 2026
- Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
September 17, 2026
- Japan Finalizes Framework for OTC-Like Drug Charge Ahead of March Rollout
September 17, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…